STCube Inc (052020) - Cash Flow Conversion Efficiency
Based on the latest financial reports, STCube Inc (052020) has a cash flow conversion efficiency ratio of -0.065x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-3.92 Billion ≈ $-2.65 Million USD) by net assets (₩60.29 Billion ≈ $40.86 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see STCube Inc (052020) total market value for the company's overall valuation and market capitalisation.
STCube Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how STCube Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
STCube Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of STCube Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of STCube Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Varia US Properties Ltd
SW:VARN
|
0.018x |
|
FENIX Resources Ltd
AU:FEX
|
0.332x |
|
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
|
0.029x |
|
Forrester Research Inc
NASDAQ:FORR
|
-0.030x |
|
Joyce Corporation Ltd
AU:JYC
|
0.524x |
|
Capral Ltd
AU:CAA
|
0.152x |
|
Donpon Precision
TWO:3290
|
0.001x |
|
MEDIFAST INC
NYSE:MED
|
0.009x |
Annual Cash Flow Conversion Efficiency for STCube Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of STCube Inc from 2009 to 2025. View 052020 stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩72.12 Billion ≈ $48.88 Million |
₩-19.78 Billion ≈ $-13.40 Million |
-0.274x | -10.84% |
| 2024-12-31 | ₩94.28 Billion ≈ $63.89 Million |
₩-23.32 Billion ≈ $-15.80 Million |
-0.247x | +64.51% |
| 2023-12-31 | ₩35.31 Billion ≈ $23.93 Million |
₩-24.61 Billion ≈ $-16.68 Million |
-0.697x | -121.89% |
| 2022-12-31 | ₩51.22 Billion ≈ $34.71 Million |
₩-16.09 Billion ≈ $-10.90 Million |
-0.314x | +70.39% |
| 2021-12-31 | ₩16.16 Billion ≈ $10.95 Million |
₩-17.15 Billion ≈ $-11.62 Million |
-1.061x | -271.33% |
| 2020-12-31 | ₩36.03 Billion ≈ $24.41 Million |
₩-10.29 Billion ≈ $-6.97 Million |
-0.286x | -4165.71% |
| 2019-12-31 | ₩28.82 Billion ≈ $19.53 Million |
₩-192.99 Million ≈ $-130.79K |
-0.007x | +95.65% |
| 2018-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩-5.96 Billion ≈ $-4.04 Million |
-0.154x | +74.13% |
| 2017-12-31 | ₩19.12 Billion ≈ $12.96 Million |
₩-11.38 Billion ≈ $-7.71 Million |
-0.595x | -386.91% |
| 2016-12-31 | ₩29.24 Billion ≈ $19.81 Million |
₩6.07 Billion ≈ $4.11 Million |
0.207x | +203.54% |
| 2015-12-31 | ₩20.91 Billion ≈ $14.17 Million |
₩-4.19 Billion ≈ $-2.84 Million |
-0.200x | -182.38% |
| 2012-12-31 | ₩8.79 Billion ≈ $5.96 Million |
₩2.14 Billion ≈ $1.45 Million |
0.243x | +203.88% |
| 2011-12-31 | ₩9.97 Billion ≈ $6.76 Million |
₩-2.33 Billion ≈ $-1.58 Million |
-0.234x | -74.55% |
| 2010-12-31 | ₩11.74 Billion ≈ $7.95 Million |
₩-1.57 Billion ≈ $-1.07 Million |
-0.134x | -244.26% |
| 2009-12-31 | ₩16.63 Billion ≈ $11.27 Million |
₩1.55 Billion ≈ $1.05 Million |
0.093x | -- |
About STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more